AGENDA DAY 2

 

Microbiome World Congress USA Day 2 2017

INNOVATION IN ALLERGIES AND VIRUSES

09:00

Keynote Presentation: The microbiota modulates gut physiology and behavioral abnormalities associated with autism

  • How can observation of Gut Brain Axis help inform us of ASD?
  • Can extended-duration treatment protocol be a promising approach to alter the gut microbiome and virome?
  • Does reversal of Autism like symptoms in mice mean Microbiome transplant treatments?
 
 
Matthew Henn
09:20

Plenary Panel: Regulations in response to the Microbiome

  • How do you work with regulators in development of Microbiome treatments?
  • How do you prevent Wild West scenarios where many companies are promoting their product and operating without oversight?
  • From FMT, Prebiotics to Probiotics, from food supplements to traditional treatments- what protocols must be established for such a wide variety of products?
  • What standards are necessary and what does solid translational evidence look like in judging the efficacy of microbial treatments?
10:00

Platinum Sponsor Session

10:20

Speed Networking

10:40 Networking coffee break

WOMEN’S HEALTH

COMMERCIALIZATION

PITCH

Scientific
11:20

Presentation: The vaginal microbiome during pregnancy and the postpartum period

  • What differences do we see in the vaginal microbiome throughout pregnancy?
  • Does the composition and structure of the pregnancy vaginal microbiome influence susceptibility to adverse pregnancy outcomes?
  • Why are there such large differences across women of different ethnicities?
Commercial
11:20

Presentation: Strategies for Developing Comprehensive Patent and Licensing Strategies

  • Steps to developing a meaningful patent portfolio for live bacterial entities and bacterially-derived products.
  • What are the difficulties of evaluating the liberty to commercialize products in an uncertain field?
  • Collaborating with pharma in drug discovery and development to accelerate microbiome therapeutics development.
Scientific
11:40

Presentation: Vaginal bacteria species can raise HIV infection risk and undermine prevention

  • How can communities in Durban, South Africa help us understand the spread of HIV?
  • Why does Gardnerella have countering effects on anti-HIV drug tenofovir?
  • Why is Lactobacillus prevalent in %90 of White US Women, but only occurs in %37 of the South African women sampled?
  • How can this data be used to alter Microbiome makeups for at risk women?
Commercial
11:40

Presentation: Obstacles to commercialization

  • As markets work to maintain health care costs, how can you build a strong value proposition and enhance your market strategy?
  • How early can you get payers involved to address issues in regulations, and formulary access guesswork?
  • What differences does Microbiome bring to the field as we are know dealing with entire living communities being transplanted?
Scientific
12:00

Sponsored case study

Commercial
12:00

Sponsored case study

12:10 ROUNDTABLES

Marina R. Walther-Antonio

Roundtable 1: Vaginal Microbiome: How do we establish “Normal” and “healthy” ecosystems?

Roundtable 2: H. Pylori Extinction: Can planned reintroduction save this near extinct bug while aiding human health?

Roundtable 3: The gut-brain axis: The other information superhighway

Roundtable 4: Patent and licensing: Strategies for Developing Comprehensive Patent and Licensing Strategies

Roundtable 5: Minority Diversity: Methods to help historically underserved communities

Roundtable 6: Lung Microbiome: What can we learn from the makeup of CF individuals?

Roundtable 7: Interdisciplinary research: How can rules and interactions in animal and environmental systems can better inform the Human Microbiome?

Roundtable 8: The Human Virome: Picking harmful pathogens from more docile viruses.

Roundtable 9: Microbiome Kits: What can these take home- send off kits really predict?

12:50 Networking lunch break

Scientific
14:09

EARLY LIFE MICROBIOTA

ALTERNATIVE APPLICATIONS

PITCH

Scientific
14:10

Presentation: C-section delivery and the criticality of Vaginal microbiome in allergies, and immune disorder

  • How influential is early microbiota on later life events?
  • Can we re-introduce the vaginal microbiome to C-section babies to avoid averse immune disorders, and allergies?
  • What effects are we seeing over the long term in c-section children?
  • Could this be the new and healthier standard for delivering newborns?
Commercial
14:10

Presentation: Cannabis Strains and regulation

  • Understanding the current issues with regulation in cannabis
  • Producing and monitoring cannabis using databases and block chain
  • Big Data and Cannabis
Scientific
14:30

Presentation: Early differences in fecal microbiota composition in children may predict overweight

  • What essential bacteria are we seeing in early development correlated with obesity?
  • Do we see histories of this throughout the family?
  • Can we fight obesity with “lean” bacteria?
Commercial
14:30

Presentation: Skin Microbiome Editing

  • Dr. Huang's lab has established a Skin Probiotic Bank.
  • How do you develop various carbohydrate-polymer conjugates as selective fermentation inducers (SFIs) for editing skin microbiome?
  • Furthermore, fifty skin probiotic bacteria can be used as probiotics for treatment of more than twenty skin diseases including acne vulgaris.
Scientific
14:50

Sponsored case study

Commercial
14:50

Sponsored case study

SKIN, ORAL, AND LUNG

FINANCING AND INVESTMENT

Scientific
15:00

Sponsored case study

Commercial
15:00

Sponsored case study

Scientific
15:10

Presentation: Oral microbiome and periodontal disease

  • By focusing on two major oral infections, periodontal disease and caries, new principles of disease emerge
  • Are these diseases resulting in dysbiosis from perturbation among relatively minor constituents in local microbial communities?
  • How do you address sampling challenges in recovering periodontal plaque biofilm whose constituents in the loose superficial plaque and in plaque most adherent to the root surface ?
Commercial
15:10

Presentation: Identifying promising innovations in a sea of products

  • How do you identify the most effective partnerships without falling into fads?
  • The payoff for being first-to-market with a successful microbiome-based therapy could be as large as that of blockbuster drugs of the past.
Scientific
15:30

Presentation: Lung Microbiome of Cystic Fibrosis Individuals

  • Culture-independent investigations have revealed a complex community of microbes in CF individuals/
  • What bacteria, fungi, and viruses, are harbored in the respiratory and gastrointestinal tracts of patients with cystic fibrosis (CF)?
  • Bacterial community composition in the respiratory and gastrointestinal tracts creates unique microbial signatures that are generally patient specific.
  • How can Multiomic analyses of airway and gut microbiota potentially refine current management strategies in CF?
Commercial
15:30

Presentation: Improving Financial Models in Partnerships

  • How and why is each party involved in a transaction? How have you defined critical roles of support?
  • How do the therapeutic area and stage of development affect the financial valuation?
  • How do small and large companies bridge the gap between approaches to asset and financial valuation?

15:50 Closing Remarks

16:00 END OF CONFERENCE

last published: 30/May/17 19:05 GMT